Teicher B A, Herman T S, Jones S M
Dana-Farber Cancer Institute, Boston, MA 02115.
Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):945-51. doi: 10.1016/0360-3016(90)90017-e.
Studies were carried out with a new, concentrated perfluorochemical emulsion (PFCE) of the perfluorochemical F44E (48% V/V). When given at 4, 1.6, or 1 g/kg in undiluted injection volumes iv 1 hr prior to a range of single doses of radiation with inspired carbogen dose modifying factors (DMF's) based on tumor growth delay (TGD) in the Lewis lung tumor of 2.5, 1.7, and 1.5, respectively, were produced. When the PFC dose was administered in a volume of 0.2 ml, the dose modifying factors produced by 4 g/kg (0.1 ml undiluted) did not change significantly (2.6), but the dose modifying factors produced by 1.6 g/kg (0.04 ml undiluted) and by 1.0 g/kg (0.025 ml undiluted) increased significantly to 2.0 and 1.8 (p less than 0.05), respectively. Using the tumor excision assay at 24 hr post treatment in the FSaIIC fibrosarcoma, administration of 6, 4, or 2 g/kg in 0.2 ml injections plus carbogen breathing 1 hr prior to and during treatment resulted in dose modifying factors of 1.5, 1.6, and 1.3, respectively. In a fractionated radiation protocol in the Lewis lung tumor using four daily fractions, a dose of 4 g/kg of PFC on days 1 and 3 proved superior to a dose of 2 g/kg daily (dose modifying factors 2.4 vs. 1.9, p less than 0.05). When a fractionated radiation regimen of 3 Gy daily X 5 and carbogen was used, PFC doses of 0.5, 1, 2, and 4 g/kg administered undiluted produced increasing tumor growth delays with increasing dose of PFCE and increasing frequency of administration. In addition, dilutions to 0.2 ml proved significantly more effective. In a 2-week fractionated radiation protocol using 2, 3, or 4 Gy daily X 5 weekly, PFCE given in 0.2 ml volume plus carbogen breathing daily at 4, 1.6, or 1 g/kg produced dose modifying factors of 2.0, 1.9, and 1.6, respectively. Finally, when used in a day 1, 3, and 5 radiation regimen for 3 weeks at 2, 3, or 4 Gy/fraction, 4 g/kg of PFCE given in a volume of 0.2 ml plus carbogen breathing produced a superior dose modifying factor (1.6) as compared with 1.6 or 1.0 g/kg (dose modifying factors 1.4 and 1.3, respectively). These results indicate that PFCE plus carbogen breathing effectively enhances the antitumor effects of both single dose and fractionated radiation.(ABSTRACT TRUNCATED AT 400 WORDS)
对一种新型的、浓缩的全氟化合物F44E(48%V/V)的全氟化学乳剂(PFCE)进行了研究。在一系列单剂量辐射前1小时,以未稀释的注射体积静脉注射4、1.6或1 g/kg,基于Lewis肺癌中肿瘤生长延迟(TGD)分别产生了2.5、1.7和1.5的吸氧碳合剂量修正因子(DMF)。当以0.2 ml的体积给予PFC剂量时,4 g/kg(0.1 ml未稀释)产生的剂量修正因子没有显著变化(2.6),但1.6 g/kg(0.04 ml未稀释)和1.0 g/kg(0.025 ml未稀释)产生的剂量修正因子分别显著增加至2.0和1.8(p小于0.05)。在FSaIIC纤维肉瘤治疗后24小时使用肿瘤切除试验,在0.2 ml注射中给予6、4或2 g/kg并在治疗前和治疗期间吸氧碳合1小时,产生的剂量修正因子分别为1.5、1.6和1.3。在Lewis肺癌的分次放疗方案中,使用每日4次分次,第1天和第3天给予4 g/kg的PFC剂量优于每日2 g/kg的剂量(剂量修正因子2.4对1.9,p小于0.05)。当使用每日3 Gy×5次并吸氧碳合的分次放疗方案时,未稀释给予0.5、1、2和4 g/kg的PFC剂量随着PFCE剂量增加和给药频率增加产生了越来越长的肿瘤生长延迟。此外,稀释至0.2 ml被证明显著更有效。在一个为期2周的分次放疗方案中,使用每日2、3或4 Gy×5次/周,以0.2 ml体积给予PFCE并每日吸氧碳合,剂量为4、1.6或1 g/kg,产生的剂量修正因子分别为2.0、1.9和1.6。最后,当在第1、3和5天进行为期3周的放疗方案中,每次剂量为2、3或4 Gy时,以0.2 ml体积给予4 g/kg的PFCE并吸氧碳合产生了优于1.6或1.0 g/kg的剂量修正因子(分别为1.6对1.4和1.3)。这些结果表明,PFCE加吸氧碳合有效地增强了单剂量和分次放疗的抗肿瘤效果。(摘要截短至400字)